N$ Pharma appoints new CEO, proposes name change
24th Feb 2026 15:13
(Sharecast News) - N4 Pharma announced the appointment of Dr David H Solomon as its chief executive on Tuesday, and unveiled plans to rebrand as Thalia Therapeutics as it pivoted towards becoming an RNA therapeutics-focused biotechnology company.
Read moreN4 Pharma reports narrower full-year operating loss
6th Jun 2025 12:14
(Sharecast News) - N4 Pharma reported a reduced operating loss of £1.22m for 2024 on Friday, down from £1.42m the prior year, as the biotech company continued to develop its proprietary Nuvec gene delivery platform.
Read moreN4 Pharma files for new UK patent
4th Dec 2024 14:46
(Sharecast News) - N4 Pharma, a pharmaceutical company specializing in RNA therapeutics, announced the filing of a new patent with the UK patent office on Wednesday, for its oral anti-inflammatory treatment targeting irritable bowel disease (IBD).
Read moreN4 Pharma reports positive progress with SRI collaboration
20th Aug 2024 10:10
(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on the development of Nuvec, a novel delivery system for cancer treatments, gene therapy, and vaccines, updated the market on its collaboration with SRI International on Tuesday.
Read moreN4 Pharma shares tank after £0.6m fundraise
7th Jun 2024 11:06
(Sharecast News) - Shares in small-cap pharma group N4 Pharma sank on Friday after the company announced a share placing and subscription to raise £630,000.
Read moreN4 Pharma shares jump on latest Nuvec developments
15th Feb 2024 13:17
(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.
Read moreN4 Pharma's Nuvec granted patent in India
19th Jan 2024 13:00
(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.
Read moreN4 Pharma subsidiary agrees work programme for glaucoma treatment
16th Jan 2024 14:05
(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.
Read moreN4 Pharma reports progress in Nuvec clinical research
8th Jan 2024 12:30
(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.
Read moreN4 Pharma upbeat on recent Nuvec developments
18th Dec 2023 11:17
(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.
Read moreN4 Pharma posts optimistic Nuvec research update
7th Dec 2023 13:20
(Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on developing the Nuvec delivery system for cancer treatments and vaccines, issued an optimistic update on its ongoing in-vitro siRNA research efforts on Thursday.
Read moreN4 Pharma picks up controlling interest in Nanogenics
28th Sep 2023 13:28
(Sharecast News) - Pharmaceutical firm N4 Pharma announced the acquisition of a controlling interest in Nanogenics on Thursday.
Read moreN4 Pharma reports progress with siRNA work
18th Apr 2023 13:13
(Sharecast News) - N4 Pharma updated the market on its ongoing research work on gene-silencing technology siRNA on Tuesday.
Read moreN4 Pharma shares tumble following placing, broker offer announcement
18th Nov 2022 08:11
(Sharecast News) - Shares in pharmaceutical company N4 Pharma tumbled on Friday after the group said it had raised £1.0m via the placing of 50.0m new ordinary shares of 0.4p each and detailed a broker offer aimed at raising as much as another £1.0m.
Read moreN4 Pharma reports success in recent 'Nuvec' testing
4th Oct 2022 13:32
(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced success in its in-vitro testing of its 'Nuvec' drug delivery system on Tuesday, loaded with two small interfering RNA (siRNA) probes.
Read more